I. Policy:
Xolair (Omalizumab)

II. Purpose/Objective:
To provide a policy of coverage regarding Xolair (Omalizumab)

III. Responsibility:
A. Medical Directors
B. Medical Management
C. Pharmacy Department

IV. Required Definitions
1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions
Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
b. provided for the diagnosis and the direct care and treatment of the Member's condition, illness disease or injury;
c. in accordance with current standards good medical treatment practiced by the general medical community;
d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and

e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment
Medical Necessity shall mean a service or benefit that is compensable under the Medical Assistance Program and if it meets any one of the following standards:

(i) the service or benefit will, or is reasonably expected to, prevent the onset of an illness, condition or disability.

(ii) the service or benefit will, or is reasonably expected to, reduce or ameliorate the physical, mental or development effects of an illness, condition, injury or disability.

(iii) the service or benefit will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for members of the same age.
DESCRIPTION:
Xolair (Omalizumab) is a recombinant humanized monoclonal antibody to immunoglobulin E (IgE). Currently, Xolair is available as a subcutaneous injection only.

CRITERIA FOR USE: Requires Prior Authorization by Medical Director or Designee

Xolair (Omalizumab) will be considered medically necessary when all of the following criteria are met:

1. **For Asthma:**
   - Must be prescribed by an allergist or pulmonologist AND
   - Insured individual must be compliant with current therapeutic regimen AND
   - Insured individual is at least 6 years of age AND
   - Physician provided documentation of a diagnosis of moderate to severe persistent asthma* with evidence of reversible airway disease [i.e. greater than 12% improvement in forced expiratory volume in one second (FEV₁) with at least 200 ml increase or at least a 20% or greater improvement in peak expiratory flow (PEF) after administration of albuterol] AND
   - Physician provided documentation of inadequate control or intolerance, despite a 3 month trial of: medium –high dose inhaled corticosteroids or systemic corticosteroids and long-acting beta agonists or leukotriene receptor antagonists AND
   - Physician provided documentation of an IgE level of greater than 30 IU/ml and less than 1300 IU/ml for individuals age 6 through 11 AND
   - Physician provided documentation of evidence of a specific allergic reactivity to a perennial aeroallergen by positive skin or blood test for a specific IgE AND
   - Known environmental triggers within the member’s control have been eliminated. AND
   - Medical record documentation that Xolair is not being used in combination with Fasenra (benralizumab), Nucala (mepolizumab), or Cinqair (reslizumab)

*Moderate persistent asthma is defined by the National Heart, Lung and Blood institute (NHLBI) as:

1. Daily symptoms
2. Daily use of inhaled short-acting beta agonist
3. Exacerbations affect activity
4. Exacerbations at least twice a week, which may last days
5. Nighttime symptoms more frequently than one time per week
6. Lung function of FEV1 less than or equal to 60% but less than 80%

*Severe persistent asthma is defined by the NHLBI as:

1. Continual symptoms
2. Limited physical activity
3. Frequent exacerbations
4. Frequent nighttime symptoms
5. Lung function of FEV1 less than or equal to 60% predicted

**The 12% improvement target value is calculated using the following methodology: The target value = baseline FEV₁ x 1.12

The actual clinical calculation is: post-treatment FEV₁ – baseline FEV₁ = % improvement baseline FEV₁

RECOMMENDED DOSING SCHEDULE:

Xolair Dosing and Administration

For individuals 12 year and older:

<table>
<thead>
<tr>
<th>Pre-treatment Serum IgE (IU/mL)</th>
<th>30-60</th>
<th>&gt; 60-70</th>
<th>&gt;70-90</th>
<th>&gt;90-150</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 30-100</td>
<td>150 mg every 4 weeks</td>
<td>150 mg every 4 weeks</td>
<td>150 mg every 4 weeks</td>
<td>300 mg every 4 weeks</td>
</tr>
<tr>
<td>&gt; 100-200</td>
<td>300 mg every 4 weeks</td>
<td>300 mg every 4 weeks</td>
<td>300 mg every 4 weeks</td>
<td>225 mg every 2 weeks</td>
</tr>
<tr>
<td>&gt; 200-300</td>
<td>300 mg every 4 weeks</td>
<td>225 mg every 2 weeks</td>
<td>225 mg every 2 weeks</td>
<td>300 mg every 2 weeks</td>
</tr>
<tr>
<td>&gt; 300-400</td>
<td>225 mg every 2 weeks</td>
<td>225 mg every 2 weeks</td>
<td>300 mg every 2 weeks</td>
<td></td>
</tr>
<tr>
<td>&gt; 400-500</td>
<td>300 mg every 2 weeks</td>
<td>300 mg every 2 weeks</td>
<td>375 mg every 2 weeks</td>
<td></td>
</tr>
</tbody>
</table>
For individuals 6 to 11 years old:

<table>
<thead>
<tr>
<th>Pre-treatment Serum IgE (IU/mL)</th>
<th>20-25</th>
<th>&gt;25-30</th>
<th>&gt;30-40</th>
<th>&gt;40-50</th>
<th>&gt;50-60</th>
<th>&gt;60-70</th>
<th>&gt;70-80</th>
<th>&gt;80-90</th>
<th>&gt;90-125</th>
<th>&gt;125-150</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 30-100</td>
<td>75mg</td>
<td>75mg</td>
<td>75mg</td>
<td>150mg</td>
<td>150mg</td>
<td>150mg</td>
<td>150mg</td>
<td>150mg</td>
<td>300mg</td>
<td>300mg</td>
</tr>
<tr>
<td>&gt;100-200</td>
<td>150mg</td>
<td>150mg</td>
<td>150mg</td>
<td>300mg</td>
<td>300mg</td>
<td>300mg</td>
<td>300mg</td>
<td>225mg</td>
<td>225mg</td>
<td>300mg</td>
</tr>
<tr>
<td>&gt;200-300</td>
<td>150mg</td>
<td>150mg</td>
<td>225mg</td>
<td>300mg</td>
<td>300mg</td>
<td>300mg</td>
<td>225mg</td>
<td>225mg</td>
<td>300mg</td>
<td>375mg</td>
</tr>
<tr>
<td>&gt;300-400</td>
<td>225mg</td>
<td>225mg</td>
<td>225mg</td>
<td>225mg</td>
<td>225mg</td>
<td>300mg</td>
<td>300mg</td>
<td>375mg</td>
<td>375mg</td>
<td></td>
</tr>
<tr>
<td>&gt;400-500</td>
<td>225mg</td>
<td>300mg</td>
<td>225mg</td>
<td>225mg</td>
<td>300mg</td>
<td>375mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;500-600</td>
<td>300mg</td>
<td>300mg</td>
<td>225mg</td>
<td>225mg</td>
<td>300mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;600-700</td>
<td>300mg</td>
<td>225mg</td>
<td>225mg</td>
<td>300mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;700-900</td>
<td>225mg</td>
<td>225mg</td>
<td>300mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;900-1100</td>
<td>225mg</td>
<td>300mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;1100-1200</td>
<td>300mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;1200-1300</td>
<td>300mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adapted from Xolair [package insert]. South San Francisco, CA: Genentech USA Inc; March 2014

Xolair must be administered in a clinical setting equipped to manage life-threatening anaphylaxis. Patients should be observed for a minimum of two hours following administration of Xolair. It is also recommended by the FDA that patients on Xolair therapy should also carry and know how to initiate emergency self-treatment for anaphylaxis.

EXCLUSIONS:
Xolair has not been shown to be effective in patients age 12 and older with an IgE level less than 30 IU/ml or greater than 700 IU/ml, or in patients age 6 through 11 with an IgE level less than 30 IU/ml or greater than 1300 IU/ml

Xolair® has not been shown to alleviate acute asthma exacerbations and should not be used for treatment of acute bronchospasm or status asthmaticus.

Non-compliance with combination therapy including inhaled or systemic corticosteroids and a long acting beta-agonist or leukotriene receptor antagonist.

AUTHORIZATION DURATION: Initial approval will be for 12 months or less if the reviewing provider feels it is medically appropriate. Subsequent approvals will be for an additional 12 months or less if the reviewing provider feels it is medically appropriate and will require medical record documentation of continued disease improvement or lack of disease progression. The medication will no longer be covered if patient experiences toxicity or worsening of disease.
2. For Chronic Idiopathic Urticaria:
   • Prescription is written by an allergist, immunologist, or dermatologist AND
   • Patient is at least 12 years of age AND
   • Diagnosis of moderate-to-severe chronic idiopathic urticaria AND
   • At least 6 week history of symptoms (e.g., hives associated with itching, angioedema) AND
   • Medical record documentation of a therapeutic failure on Xolair 150 mg dose, when Xolair 300 mg dose is requested AND
   • Medical record documentation of contraindication to, therapeutic failure on, or intolerance to a four week trial of ALL of the following treatment alternatives:
     ▪ At least two different high dose antihistamines
     ▪ Maximum dose antihistamine(s) used in combination with a leukotriene receptor antagonist (e.g., montelukast)
     ▪ High dose antihistamine used in combination with H₂ receptor antagonist (e.g., ranitidine)
     ▪ Dose advancement of potent antihistamine (e.g., hydroxyzine or doxepin)

AUTHORIZATION DURATION: Initial approval will be for 12 months or less if the reviewing provider feels it is medically appropriate. Subsequent approvals will be for an additional 12 months or less if the reviewing provider feels it is medically appropriate and will require medical record documentation of continued disease improvement or lack of disease progression. The medication will no longer be covered if patient experiences toxicity or worsening of disease.

LIMITATIONS:
The Plan considers the use of Xolair for conditions other than those listed under Indications to be experimental, investigational or unproven. There is insufficient peer-reviewed, published medical literature to support the use of Xolair for any of the following:

   • Other allergic conditions or other forms of urticarial besides chronic idiopathic urticaria.
   • Acute bronchospasm or status asthmaticus.
   • Pediatric patients less than 12 years of age.

Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in MP 15 - Experimental Investigational or Unproven Services or Treatment.

LINE OF BUSINESS:
Eligibility and contract specific benefit limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy.

This policy will be revised as necessary and reviewed no less than annually.

Devised: 10/27/03

Revised: 5/05 expanded criteria for coverage; 5/07 added FDA warning; 3/08 criteria change; 11/09 (added formulary alternatives, dosing chart); 2/13, 09/16/14 (added new indication), 3/24/15 changed auth duration, 3/23/17 (updated age criteria, PARP), 5/15/18 (criteria updated)

Reviewed: 6/06, 12/10; 2/12; 09/16/14, 3/31/16, 1/30/17, 10/31/17, 4/22/19, 2/1/20